A5083412032- Ovarian cancer diagnosis and treatment
- Immune cells in cancer
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Intraperitoneal and Appendiceal Malignancies
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Mathematical Biology Tumor Growth
- Reproductive System and Pregnancy
- Cancer-related molecular mechanisms research
- Toxin Mechanisms and Immunotoxins
- Neuroinflammation and Neurodegeneration Mechanisms
- Cancer, Stress, Anesthesia, and Immune Response
- Advanced Electron Microscopy Techniques and Applications
- Cancer Mechanisms and Therapy
- MRI in cancer diagnosis
- Signaling Pathways in Disease
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Galectins and Cancer Biology
- Peptidase Inhibition and Analysis
KU Leuven
2019-2024
Oncoinvent (Norway)
2020-2024
Cancer Institute (WIA)
2021-2024
Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers immunostratification and immunotherapy designing. However, current approaches immunobiomarkers' detection are largely quantitative, which is unreliable assessing functional immunodynamics of patients with cancer. Hence, we aimed to design a biomarker modality capturing signaling in cancer reliable immunostratification.We used data-driven silico framework,...
The role of the innate immune system in ovarian cancer is gaining importance. relevance tumor-associated macrophages (TAM) insufficiently understood. In this pilot project, comprising immunofluorescent staining 30 biopsies taken from 24 patients with cancer, we evaluated presence total TAM (cluster differentiation (CD) 68 expression), M1 (major histocompatibility complex (MHC) II and M2 (anti-mannose receptor C type 1 (MRC1) blood vessel diameter. We observed a high M1/M2 ratio low-grade...
The lack of immune synergy with conventional chemoradiation could explain the failure checkpoint inhibitors in current clinical trials for high-grade gliomas (HGGs).To analyze impact radiotherapy (RT), Temozolomide (TMZ) and antiprogrammed cell death protein 1 (αPD1) (as single or combined treatments) on microenvironment experimental HGGs.Mice harboring neurosphere /CT-2A HGGs received RT (4 Gy, dose), TMZ (50 mg/kg, 4 doses) αPD1 (100 μg, 3 as monotherapies combinations. influence survival,...
In the context of high-grade gliomas (HGGs), very little evidence is available concerning optimal radiotherapy (RT) schedule to be used in radioimmunotherapy combinations. This studied was aimed at shedding new light this field by analyzing effects RT dose escalation and fractionation on tumor microenvironment experimental HGGs.Neurospheres (NS) CT-2A HGG-bearing C57BL/6 mice were treated with stereotactic RT. For dose-escalation experiments, received 2, 4 or 8 Gy as single administrations....
The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. underlying mechanisms are not clearly understood.The amount was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis retrospective cohort 214 women with cancer, an ordinal manner (amount ascites: none, limited, moderate, abundant). In prospective comprising 45 IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-β (transforming factor) and CCL-2 [chemokine (C-C)...
Background Recently, several promising treatments for high-grade gliomas (HGGs) failed to provide significant benefit when translated from the preclinical setting patients. Improving animal models is fundamental overcome this translational gap. To address need, we developed and comprehensively characterized a new in-vivo model based on orthotopic implantation of CT-2A cells cultured in neurospheres (NS/CT-2A). Methods Murine methylcholanthrene-induced HGG (C57BL/6 background) were monolayers...
Background Ovarian cancer is the leading cause of mortality among gynecological malignancies. Carboplatin and poly (ADP-ribose) polymerase inhibitors (PARPi) are often implemented in treatment ovarian cancer. Homologous recombination deficient (HRD) tumors demonstrate increased sensitivity to these treatments; however, many patients homologous proficient (HRP). TTFields non-invasive electric fields that induce an HRD-like phenotype various types. The current study aimed investigate impact...
In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to successful combinatorial treatment implies knowledge of the immune changes that are induced by chemotherapy and surgery. Methodology: Patients with new d cancer diagnosis underwent longitudinal blood samples at different time points during primary treatment. Results.: Ninety patients were included study (33% debulking surgery (PDS) adjuvant (ACT), 61% neo-adjuvant (NACT) interval (IDS), 6% only). Reductions...
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of radioimmunoconjugate to locally target mesothelioma cells been proposed treatment. CD146, upregulated in but not healthy tissues, is promising target. This study characterized CD146 expression binding/internalization kinetics CD146-targeting...
Novel treatment strategies are needed to provide a better prognosis for ovarian cancer. For this purpose, the current study was designed evaluate effects of different types particle drug carriers on tumor response and immune microenvironment (TME) after intraperitoneal (IP) administration in murine model. Mice with ID8-fLuc cancer were injected IP pegylated liposomes, hydroxyapatite, polystyrene, poly(lactic-co-glycolic acid) (PLGA) calcium carbonate (CaCO3) microparticles effect candidate...
Abstract Background The ADNEX model (Assessment of Different NEoplasias in the adnexa) is best performing to predict risk malignancy (binary) and type (multiclass) ovarian tumors. immune system plays a role onset progression cancer. Preliminary research has suggested that immune-related biomarkers can help discrimination We aimed assess which proteins have most additional diagnostic value addition ADNEX’ clinical ultrasound predictors. Materials methods In this exploratory study, 1086...
Abstract Introduction Contrarily to clinical trials, where glioblastoma (GBM) patients are usually heavily pre-treated (surgery, radiotherapy (RT) and temozolomide (TMZ)) before receiving the experimental therapies, in preclinical GBM studies treatments have mostly been administered as monotherapy or combined with a very limited part of standard care. This discrepancy can explain failed translation preclinically successful treatments. study is aimed at evaluating feasibility survival impact...
A novel alpha-therapy consisting of 224Ra-labeled calcium carbonate microparticles (224Ra-CaCO3-MP) has been designed to treat micrometastatic peritoneal disease via intraperitoneal (IP) administration. This preclinical study aimed evaluate its efficacy and tolerability when given as a single treatment or in combination with standard care chemotherapy regimens, syngeneic model ovarian cancer immune competent mice. Female C57BL/6 mice bearing ID8-fLuc were treated 224Ra-CaCO3-MP 1 day after...
<h3>Introduction/Background</h3> Tumor Treating Fields (TTFields) provide non-invasive cancer treatment through continuous delivery of alternating electrical fields, administered arrays on the skin patients. TTFields have been investigated in combination with weekly paclitaxel for recurrent ovarian (OC) (INNOVATE, NCT02244502). This phase 2 study showed good tolerability and promising survival results provided motivation ongoing 3 (INNOVATE-3/ENGOT-ov50/GOG-3029, NCT03940196). Besides...